In 2016, a scientific review published by a Washington-based lobby group ignited a firestorm, concluding that the evidence underpinning dietary guidelines recommending limits on added sugars was of "low quality" and failed to "meet criteria for trustworthy recommendations." This influential paper, funded by a consortium of multinational food and agrochemical giants including Coca-Cola and Monsanto, was later accused of "hijacking the scientific process in a disingenuous way to sow doubt and jeopardize public health." The methods employed by these corporate sugar titans to achieve this outcome warrant a closer examination of their strategic manipulation of scientific evaluation processes.
The lobby group, in its paper titled "The Scientific Basis of Guideline Recommendations on Sugar Intake," utilized the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. This system, designed to imbue clinical guidelines with greater evidence-based rigor, was initially developed for drug recommendations. By applying GRADE, the industry-funded review asserted that the "overall quality of evidence to support [such] recommendations was low to very low." This strategic application of a framework designed for pharmaceutical interventions to nutritional science became a cornerstone of their campaign to undermine established dietary advice.
The GRADE System: A Double-Edged Sword
The GRADE system, a globally recognized methodology, aims to standardize the assessment of evidence quality and the strength of recommendations. It typically prioritizes evidence from randomized controlled trials (RCTs) as the gold standard due to their ability to minimize bias. The system categorizes evidence quality into four levels: high, moderate, low, and very low. RCTs are generally considered to yield high-quality evidence, while observational studies, such as cohort studies and case-control studies, are often downgraded due to inherent limitations in establishing causality.
The strength of GRADE lies in its systematic approach, which enhances transparency and consistency in guideline development. However, its inherent bias towards RCTs presents a significant challenge when applied to dietary research. Unlike drug trials, where participants can be randomly assigned to receive a medication or a placebo, and remain unaware of their assignment, dietary interventions are far more complex.
The Inherent Limitations of Applying RCTs to Diet
The fundamental difficulty in conducting RCTs for dietary interventions lies in the nature of food consumption. Participants cannot be easily blinded to their dietary intake; the act of eating specific foods or adhering to particular eating patterns is inherently observable and distinguishable. This lack of blinding can introduce significant bias, as participants may alter their behavior or report their intake differently if they are aware of their assigned diet.
Furthermore, the long-term health consequences of dietary patterns, such as the development of chronic diseases like cancer or cardiovascular disease, often take decades to manifest. RCTs, due to their cost and logistical demands, are typically limited to weeks or months, making them insufficient for evaluating the long-term impact of diet on these complex conditions. For instance, while an RCT might assess the short-term effects of a particular diet on weight loss, it is impractical to randomize individuals to different lifelong diets and expect adherence for the decades required to observe cancer prevention.
The tobacco industry’s historical playbook offers a stark parallel. Faced with overwhelming evidence linking smoking to lung cancer, the industry employed tactics to create doubt and delay regulatory action. A key strategy was the promotion of "sound science" campaigns, which emphasized the need for absolute scientific certainty, often by demanding the impossible standard of RCTs for causal links that could be demonstrably established through other rigorous epidemiological methods. Philip Morris, for example, invested heavily in PR firms and legal strategies to promote a narrow definition of scientific proof that would obscure the harms of tobacco.
The "Sound Science" Tactic: A Legacy of Doubt
The "sound science" movement, pioneered by industries seeking to discredit scientific consensus on harmful products, has been effectively co-opted by the food industry, particularly concerning sugar. This tactic involves questioning the validity of existing research by demanding the highest level of evidence, often in areas where such evidence is practically unattainable. By highlighting the perceived "low quality" of evidence derived from observational studies, these industries aim to create confusion and erode public trust in dietary recommendations.
The tobacco industry’s approach was to recruit other industries and issues under the "sound science" umbrella to obscure their direct role. They sought to enshrine "good epidemiological practices" that would make it impossible to conclude that secondhand smoke, and by extension other environmental toxins, caused diseases. This strategy aimed to shift the burden of proof and create a perpetual state of scientific uncertainty.
As stated by public health professionals, the "sound science" movement is not an organic effort from within the scientific community to improve discourse, but rather a sophisticated public relations campaign orchestrated by industry executives and lawyers. Their objective is to manipulate the standards of scientific proof to serve corporate interests, extending beyond tobacco to potentially include the food, plastics, and chemical industries. This approach goes beyond merely creating doubt; it seeks to fundamentally alter the accepted standards of scientific evidence.
The Precedent of Hormone Replacement Therapy
The limitations of exclusively relying on RCTs for certain health recommendations were vividly illustrated by the Premarin story. For a decade, organizations recommended hormone replacement therapy (HRT) for postmenopausal women based on observational data suggesting a reduction in heart attacks. However, when subjected to rigorous, randomized, double-blind, placebo-controlled trials, HRT was found to increase the risk of heart attacks, strokes, and breast cancer. This case underscores the necessity of RCTs for drug evaluations, where they are feasible and ethically sound.
However, the analogy breaks down when applied to diet. The ethical implications of randomizing infants to sleep on their stomachs or backs to study Sudden Infant Death Syndrome (SIDS) are profound. Yet, the "back to sleep" campaign, driven by observational studies demonstrating a link between stomach sleeping and SIDS, led to a dramatic reduction in infant mortality rates. This highlights that sufficient evidence to make life-saving lifestyle recommendations can be obtained without the exclusive reliance on RCTs.
Big Sugar’s Strategic Application of GRADE
The 2016 review leveraged the GRADE system’s emphasis on RCTs to cast doubt on guidelines recommending sugar reduction. By framing the evidence base for these guidelines as "low to very low" according to GRADE, the industry-funded report aimed to create an impression that the scientific foundation for such recommendations was weak. This strategy is particularly effective because the GRADE system itself is designed to be transparent and objective, lending an air of scientific legitimacy to the industry’s claims.
The implications of this strategy are significant. When public health bodies and dietary guidelines are perceived as lacking robust scientific backing, public adherence to these recommendations diminishes. This can lead to continued high sugar consumption, contributing to the rising rates of obesity, type 2 diabetes, cardiovascular disease, and other metabolic disorders.
Broader Implications and Industry Playbooks
The tactics employed by the sugar industry mirror those historically used by the tobacco industry. The concept of "creating doubt and controversy" about scientific evidence, while also attempting to change the fundamental standards of scientific proof, is a well-established corporate strategy. This approach can be generalized to other industries facing scientific scrutiny, including those in the food, chemical, and plastics sectors.
The corporate playbook for undermining dietary guidelines often involves:
- Funding Research: Sponsoring studies that yield favorable results or that can be used to selectively support industry narratives.
- Lobbying and Advocacy: Engaging in direct lobbying efforts to influence policy and regulatory decisions.
- Public Relations Campaigns: Disseminating misleading information through media channels and public forums to shape public perception.
- Challenging Scientific Consensus: Creating artificial controversy by amplifying dissenting voices or questioning established scientific findings.
- Manipulating Scientific Evaluation Frameworks: As seen with the GRADE system, strategically applying methodologies to cast doubt on unfavorable evidence.
The broader impact of these tactics is a public health crisis exacerbated by misinformation and a delay in implementing evidence-based interventions. The challenge for public health professionals lies in navigating this complex landscape, armed with a nuanced understanding of scientific evidence and the manipulative strategies employed by industries with vested interests.
As Sir Austin Bradford Hill, a pioneer of the randomized controlled trial, wisely stated, "Any belief that the controlled trial is the only way would mean not that the pendulum had swung too far but that it had come right off its hook." This sentiment is crucial when evaluating dietary guidelines. While RCTs are invaluable, they are not the sole arbiter of scientific truth, particularly in complex areas like nutrition where observational studies, epidemiological data, and long-term cohort analyses provide indispensable insights. The systematic devaluing of this broader evidence base by industry-funded groups poses a significant threat to public health, echoing a well-worn and dangerous playbook.
